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with multiple infected, deep ulcers showing destruction of
subcutaneous fat and allowing muscle visualization (Fig. 1).
In 2010, the patient had already been treated with
several doses of corticosteroids (20–60 mg/day), with onlyIntroduction
Livedoid vasculopathy (LV) is a recurrent, chronic and painful
skin disease, characterized by lesions that arise as punctate or
lenticular purple-colored macules and/or papules occurring in
the lower limbs (lower third of the legs and ankles), which
commonly progress to ulceration, and subsequently heal
slowly over weeks or months, giving rise to pearly atrophic
scars (white atrophy), punctate telangiectasia, and brownish
pigmentation, accompanied by a racemous livedo.1–3
The disease usually settles bilaterally in the legs, often
causing edema in the lower third of the limbs. Livedoid vascu-
lopathy mainly affects women (about three women for every
man) between 15 and 50 (mean 32) years old.2,3
We  report a case of a female patient with livedoid vascu-
lopathy, with excellent healing of lower limb ulcers after using
an anti-TNF agent. Study conducted at Hospital and Maternity Celso Pierro, Pontifícia U
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Female patient, 60, married, tradeswoman. Twelve years ago,
this patient began a clinical picture of bilateral ulcers in her
legs and feet, accompanied by color changes, with intense
worsening in cold weather. Initially, the superﬁcial ulcers were
few in number, with a gradual increase in their number and
depth. The patient had no other systemic and/or joint com-
plaint, no comorbidities, and no family history of rheumatic
disease.
On physical examination, no change in cardiac, pulmonary
and musculoskeletal systems was noted. The lower limbs (legs
and feet) presented with an intense livedo racemosa (Fig. 1),niversidade Católica de Campinas, Campinas, SP, Brazil.
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Fig. 1 – Livedo Racemosa on a left foot, and ulceration in right leg.
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Fig. 2 – Improvement of ulcers and livedo racemosa in rightlight improvement and always with recurrent lesions after
ecreasing the dose. She had also been treated with a com-
ination of aspirin 200 mg/day and pentoxifylline 800 mg/day,
ith no clinical improvement. In 2011, the patient was treated
ith methotrexate 15 mg/week in association with corticoste-
oids, but to no avail.
Her lab work showed no change in blood count, renal
unction, liver function and urinary sediment. The comple-
ent proteins (C3 and C4) were normal; ANA 1/320 with a
ne speckled pattern. Anti-DNA, anti-RNP, anti-Sm, anti-RO,
nticardiolipin antibodies (IgM and IgG), lupus anticoagu-
ant, rheumatoid factor, and cryoglobulins were negative; ESR:
5 mm,  and CRP: 2.4 mg/dL. An ulcer biopsy was obtained,
nd the pathological examination described occlusion of der-
al  blood vessels, caused by deposition of intravascular ﬁbrin;
nd thrombosis associated with segmental hyalinization and
ndothelial proliferation, with the presence of a discrete
erivascular inﬂammatory inﬁltrate, suggestive of livedoid
asculopathy/Milian’s white atrophy.
In 2012, after the failure of multiple treatments, a combi-
ation of the anti-TNF agent adalimumab and corticosteroids
as instituted, with a subsequent decrease of corticosteroids.
 year after this therapeutic regimen, the patient showed a
igniﬁcant improvement of her lower limb ulcers (Fig. 2).
iscussion
ivedoid vasculopathy is a disease whose pathophysiology is
ot well understood. This fact reﬂects the many  synonyms
or this disease, such as Milian’s white atrophy, livedo vasculi-
is, segmental hyalinizing vasculitis, livedoid vasculitis, livedo
eticularis with summer ulcers, and PURPLE (Purpuric painful
lcers with Reticular Pattern of the Lower Extremities).1
This vasculopathy may be primary or secondary. In the
rst type, this condition is not associated with any other
isease. On the other hand, the secondary form is com-
only related to thrombophilia (factor V Leiden mutation,
rotein C and/or S deﬁciency, hyperhomocysteinemia, pro-
hrombin gene mutation), and to connective tissue diseases
SLE, cryoglobulinemia, APS). Therefore, in the face of a sus-
icion of this diagnosis, it is important to start a clinicalleg and foot.
investigation of the patient and his/her family, with partic-
ular emphasis on hypercoagulable states and inﬂammatory
diseases.1,4 We  suggested the exclusion of all those condi-
tions that may determine punch-like (“piecemeal”) reticulated
ulcerations and difﬁcult-to heal conditions; such disorders can
cause stellate-like whitish scars (i.e., septic and leukocytoclas-
tic vasculitides).2
In addition to a complete physical examination, the doc-
tor should request a complete blood count, coagulation tests,
CRP levels, ﬁbrinogen, anti-nuclear factor, anti-DNA antibody,
rheumatoid factor, antiphospholipid antibodies, and cryoglob-
ulins. In addition, it is important to get a Doppler ultrasound of
lower limbs, with the aim of discarding chronic venous stasis.4
With the exception of ﬁbrinogen dosage, the patient in this
study obtained results for all tests suggested.
Originally, this entity was considered as a true vasculitis,
wherein the ischemic-thrombotic changes were due to a pri-
mary  inﬂammatory process. However, many  authors no longer
accept this concept. Currently, one believes that the primary
pathophysiological mechanism is a vaso-occlusive process
resulting from thrombosis of small- and medium-caliber der-
mal  vessels, considering that inﬂammatory changes are found
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primarily in late lesions, consisting of a secondary event. The
thrombosis into these vessels would occur through multiple
changes in the coagulation cascade – from platelet dysfunc-
tion to a defect in the production of tissue plasminogen
activator.1–5
Furthermore, the link between coagulation and inﬂam-
mation has been investigated in cases of LV, taking into
account that thrombin activates those receptors activated by
protease type 1 (which, in inﬂammatory cells, produce inﬂam-
matory mediators such as IL-6, IL-8, chemotactic substances of
monocytes, and adhesion molecules) and, moreover, recruits
leukocytes toward the intravascular environment.1
As noted in this patient’s biopsy, in the histological descrip-
tion of livedoid vasculopathy one can observe occlusion of
vessels of the dermis through deposition of intravascular ﬁbrin
and by intraluminal thrombus, besides segmental hyaliniza-
tion and endothelial proliferation. The perivascular mixed
inﬂammatory (neutrophilic at its onset, and then lympho-
cytic) inﬁltrate arises at a minimum degree. In general, direct
immunoﬂuorescence shows deposition of immunoglobulins,
ﬁbrin, and components of complement.1–4
Largely due to its uncertain pathogenesis, there is no a
single effective treatment for this skin condition. Current
treatment options are based on reports of isolated cases, or
of case series. Most treatments aim to improve the physical
manifestations and alleviate the pain.5
The therapeutic arsenal – described in the literature
– consists of antiplatelet and anticoagulant agents, ﬁb-
rinolytic agents, vasodilators, phototherapy with PUVA,
hyperbaric chamber, and immunosuppressants (corticoste-
roids, cyclosporine, sulfasalazine, immunoglobulin). All these
agents are described in the literature, in attempts of ulcer
treatment.5
Among antiplatelet drugs and hemorheologic agents,
acetylsalicylic acid and pentoxifylline, respectively, have been
successfully used in the treatment of LV, and their association
is one of the most commonly used therapeutic regimens.5
Yang et al. reported that 13 of 27 patients with LV responded
to a combination of local care of wounds, rest, and low-
dose aspirin in combination with dipiridamol.6 A case report
described the successful treatment of LV associated with
sickle cell trait with ASA.7 Sams et al. reported the use
of pentoxifylline in eight patients; in seven, a signiﬁcant
improvement of ulcerations was noted.8 Our patient did not
beneﬁt from the combination of these two drugs.
Immunosuppressive agents are generally used for recur-
rent cases, such as rescue therapy.9 However, the use of
methotrexate was not effective for our patient.
Sheinberg et al. described a case of a 38-year old female
with LV refractory to treatment with anticoagulants and
immunosuppressants, and who  obtained a good response
after the institution of rituximab. These authors reported
that, in spite of its unknown etiology, LV correlates strongly
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with immune complex diseases; and its histology shows
consistently inﬂammatory inﬁltrates; it may come that B lym-
phocytes are involved in the pathogenesis of this disease,
but further studies are needed to clarify this point.10 In this
report, we have succeeded in healing our patient’s ulcers
after the use of adalimumab. To our knowledge, this is the
ﬁrst report describing the treatment of LV with an anti-TNF
agent.
Tumor necrosis factor (TNF) contributes to the develop-
ment of thrombosis, because TNF stimulates the expression of
tissue factor by endothelial cells (i.e. an activator of the extrin-
sic coagulation pathway) and of thrombomodulin (a potent
inhibitor of coagulation).11 Thus, adalimumab, which is a fully
human anti-tumor necrosis factor monoclonal antibody, can
reduce the formation of thrombi into dermal vessels, actively
participating in the pathophysiology of livedoid vasculopathy
and providing a new perspective to its treatment.
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